The Federal Circuit’s refusal to reconsider its ruling forcing Teva to delist asthma-inhaler patents from the FDA’s Orange ...

Late last year we reported on the United States Court of Appeals for the Federal Circuit decision holding that certain device patents should not ...

Operator: Good afternoon, and welcome to the Evoke Pharma, Inc. Fourth Quarter and Full Year 2024 Earnings Conference Call. Currently, all callers have been placed in a listen-only mode.

In a precedential opinion issued on March 6, the Federal Circuit affirmed the US District Court for the Eastern District of Virginia that the ...

IPA also stated that while generics are priced lower than the corresponding brands, it is unfair and unacceptable to link quality with cost.

The USFDA has established an office in India to oversee the number of Indian manufacturers qualified to supply generic ...

Good afternoon, and welcome to the Evoke Pharma fourth quarter and full-year 2024 earnings conference call. (Operator Instructions) Please be advised that today's call is being recorded. I would now ...

A much-anticipated meeting between President Donald Trump and representatives of the pharmaceutical industry took place ...

Asserting that quality standards are not region-dependent, the Indian Pharmaceutical Alliance (IPA) on Wednesday refuted the ...

Q4 2024 revenue increased 24.6% over Q3 2024; Full-year 2024 revenue grew 97.8% year-over-yearStrong growth in key commercial metrics, including ...

Q4 2024 Earnings Call Transcript March 6, 2025 Phathom Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0 ...

Evoke Pharma Inc (EVOK) nearly doubles its annual revenue, reduces net loss, and outlines ambitious growth strategies for ...